Solid Dosage
GEA provides proven solutions for manufacturing even the most challenging dosage forms of cardiovascular medication.
There are many types and combinations of medicines available to treat coronary heart disease (CHD), high blood pressure or heart failure, including anticoagulants, antiplatelet medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, calcium channel blockers, digoxin and diuretics.
Whatever the active ingredient, GEA provides proven solutions for even the most challenging dosage forms, such as MUPS tablets, effervescents and multi-layer dosage forms, as well as granules, pellets, modified/extended release formulations, powders designed for direct tableting or capsule filling and high-volume applications.
Still an important unit operation, coating is used to either add color, protect, mask the taste or create a modified release form in pharmaceutical production. GEA offers a range of standard, innovative, batch and continuous coater systems
Plus, as containment experts, the company offers the largest selection of solutions for contained processing based on a thorough containment risk analysis.
Providing increased yields, lower utility consumption and reduced waste, continuous manufacturing presents a new approach to high-volume oral dosage form production and meets the industry’s demands for faster product development, reduced costs, improved production economics and increased manufacturing flexibility.
Showing 4 of 27
Combining process monitoring using online analyzers, together with solid process engineering principles and advanced process modelling techniques will enable processes to be actively controlled in order to compensate for input variations.
Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
The impact of global warming is increasingly apparent all over the world. Towns and cities everywhere face the same challenge: providing their communities with reliable, affordable, sustainably sourced heat. GEA spoke with an expert in the field, Kenneth Hoffmann, Manager, Heat Pumps at GEA Heating & Refrigeration Technologies, about tackling global warming faster.
Something caught Farmer Tom's eye. Instead of another product demo, GEA showcased innovations via AR. That's only the start of GEA's interactive digital farm.
GEA scientists are working with researchers at the Graz University of Technology to configure a homogenization process and technology that turns eucalyptus pulp into 3D-printed, organic structures mimicking human veins, arteries and other tissues.